Siemens Healthineers鈥� Varian has introduced the next-generation microwave ablation solution, IntelliBlate, in Europe to treat soft tissue tumours.
Tailored to offer predictability and control, the CE-marked solution is said to provide European clinicians and patients with an intuitive, integrated, and minimally invasive treatment alternative.
Varian noted that this therapeutic device enhances Siemens Healthineers鈥� imaging and software solution suite, which includes myAblation Guide, myNeedle Laser guidance system, and ultrasound for treatment management.
The addition of the device, which generates controlled spherical ablation zones for predictable treatment outcomes, facilitates clinicians in planning, placing, treating, monitoring, and confirming ablation therapy within a single environment, streamlining workflow.
The Ximitry probe, a new feature of IntelliBlate, includes thermocouples for continuous temperature monitoring, providing clinicians with real-time data to inform treatment decisions.
The system’s compact and portable design, with two generators in one system, features an intuitive interface for quick setup and pre-programmed settings, decreasing procedural hurdles.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLast year, the US Food and Drug Administration (FDA) granted 510(k) clearance for the IntelliBlate microwave ablation system.
The company noted that following its FDA market clearance last year, IntelliBlate’s entry into the European market coincides with increasing clinical evidence supporting thermal ablation.
The Phase III COLLISION trial highlighted thermal ablation’s effectiveness, comparable to surgical resection, in the treatment of colorectal liver metastases with fewer complications and shorter hospital stays.
Varian interventional solutions president Franck Facchini said: 鈥淭he results of the COLLISION trial mark a milestone in how we think about ablation. We have reached the point where the clinical evidence unrefutably supports the use of thermal ablation as a first-line treatment option, and not just an option for patients who cannot undergo surgery.
鈥淚ntelliBlate was designed to meet this shift in care, combining precision with intelligent software and imaging in a solution that fits seamlessly into modern cancer care workflows.鈥�
